Blood Transfusion Service is a vital part of the National Health Service and there is no substitute for Human Blood and its components. Increasing advancement in the field of Transfusion technology has necessitated to enforce stricter control over the quality of Blood and its products.
In most of the developed countries, the blood banking system has advanced in all facets of donor management, storage of blood, grouping and cross-matching, testing of transmissible diseases, rationale use of blood, and distribution.
The Govt. has full responsibility for the blood program even though, in some countries, the management of blood transfusion services is delegated fully or partly to an appropriate non-governmental organization (NGO) working on a non-profit basis, e.g. Red Cross Society.
When an NGO is assigned this responsibility, the Govt. should formally recognize it and give a clear mandate to formulate the national blood policy, it is important to consider policy decisions enforcing appropriate regulations or necessary functions of health service to ensure high-quality service and safe blood.
To improve the standards of Blood and its components, the Central Govt. through the Drugs Controller General of India, has formulated comprehensive legislation to ensure a better quality control system for the collection, storage, testing, and distribution of blood and its components.
Central Govt. amended from time to time the existing requirements of Blood Banks in the Drugs & Cosmetics Act, 1940, and Rules thereunder to meet the latest standards. Consequent to a public litigation case recently, the Supreme Court of India directed the Central Govt. to enact comprehensive legislation on Blood Banks in the collection, storage, testing, and distribution of blood and its components.
In this context, the office of the Drugs Controller General of India made draft rules to further amend the existing law in the Drugs & Cosmetics Act, 1940, and Rules thereunder to meet the direction of the Hon'ble Supreme Court to improve the blood banking system in the country.
Government of India published in the year 2002 the National Blood Policy. The objective of the policy is to provide a safe, adequate quantity of blood, blood components, and products. The main aim of the policy is to procure non-remunerated regular blood donors by the blood banks.
The policy also addresses various issues about technical personnel, research, and development and eliminates profiteering by the blood banks by selling blood. The policy also envisages that fresh licenses to stand-alone blood banks in the private sector shall not be granted and renewal of such blood banks shall be subjected to thorough scrutiny
Human blood is covered under the definition of 'Drug' under Sec. 3(b) of Drugs & Cosmetics Act. Hence, it is imperative that Blood Banks need to be regulated under the Drugs & Cosmetics Act and rules thereunder.
In the year 1967, the Central Govt. (Ministry of Health) enacted a separate provision in Schedule F Part XII B of Drugs & Cosmetics Rules. Various requirements such as Accommodation, Technical staff, equipment, etc. for the operation of the blood bank were included in this Part.
State Drugs Controllers were authorized to issue the licenses for blood banks. The standards for 'Whole Human Blood' were prescribed in Indian Pharmacopoeia.
Due to the prevalence of the AIDS virus, the Ministry of Health & Family Welfare (Govt. of India) issued a notification in the year 1989 under the Drugs and Cosmetics Rules and made the test of HIV 1&2 antibodies of Whole Human Blood a mandatory requirement before transfusion.
It is imperative that each unit of blood and blood products were regulated in the year 1990 and 3 laboratories viz. NICD Delhi, NIV Pune, and CMC, Vellore were notified to function as a laboratory under 3A of Drugs and Cosmetics Rules to test HIV antibodies in respect of human blood and human blood products.
As trained technicians were not available in the Blood Banks to carry out the test for HIV 1&2 antibodies, the Ministry of Health & Family Welfare notified 112 Surveillance Centres to act as a testing lab for the blood banks for carrying out the above test (ZBTC). The list of 112 Surveillance Centres is annexed.
Following M/s. Ferguson's Report (which brought out various deficiencies about quality control of blood and blood products etc. in the year 1990 and based on concerns expressed in different fora and Parliament, the D&C Rules were again amended (Rules 68A, Part XB and Part XIIB of Schedule F) in the year 1992-93 and Drugs Controller General (India) was vested with the power of Central Licence Approving Authority (CLAA) to approve the license of notified drugs viz. Blood and Blood Products, I.V. Fluids and Vaccines and Sera.
The requirement of a blood bank is inserted in Part X-B of the Drugs and Cosmetics Rules, 1945. The Rules from 122F to 122P explain the various procedure of making applications by a blood bank, fees to be paid for grant/renewal of licence by the applicant and conditions of licence to be followed by the applicant after grant/renewal and conditions of licence to be followed by the applicant after grant/renewal of licnece.
Meditech Technologies India Private Limited has diversified to become one of India's most trusted brands with headquartered in Chennai and Nashik, India with a strong presence in many countries across the globe.
Copyright © All Rights Reserved | Meditechindia.org